EP1218025A4 - Use of mullerian inhibiting substance for treating excess androgen states - Google Patents

Use of mullerian inhibiting substance for treating excess androgen states

Info

Publication number
EP1218025A4
EP1218025A4 EP00963414A EP00963414A EP1218025A4 EP 1218025 A4 EP1218025 A4 EP 1218025A4 EP 00963414 A EP00963414 A EP 00963414A EP 00963414 A EP00963414 A EP 00963414A EP 1218025 A4 EP1218025 A4 EP 1218025A4
Authority
EP
European Patent Office
Prior art keywords
inhibiting substance
treating excess
mullerian inhibiting
excess androgen
states
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00963414A
Other languages
German (de)
French (fr)
Other versions
EP1218025A1 (en
Inventor
Patricia K Donahoe
Jose Teixeira
Eric Fynn-Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1218025A1 publication Critical patent/EP1218025A1/en
Publication of EP1218025A4 publication Critical patent/EP1218025A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP00963414A 1999-09-14 2000-09-14 Use of mullerian inhibiting substance for treating excess androgen states Withdrawn EP1218025A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15367499P 1999-09-14 1999-09-14
US153674P 1999-09-14
US15394099P 1999-09-15 1999-09-15
US153940P 1999-09-15
PCT/US2000/025094 WO2001019387A1 (en) 1999-09-14 2000-09-14 Use of mullerian inhibiting substance for treating excess androgen states

Publications (2)

Publication Number Publication Date
EP1218025A1 EP1218025A1 (en) 2002-07-03
EP1218025A4 true EP1218025A4 (en) 2005-06-01

Family

ID=26850750

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00963414A Withdrawn EP1218025A4 (en) 1999-09-14 2000-09-14 Use of mullerian inhibiting substance for treating excess androgen states

Country Status (5)

Country Link
EP (1) EP1218025A4 (en)
JP (1) JP2003509377A (en)
AU (1) AU7483000A (en)
CA (1) CA2384991A1 (en)
WO (1) WO2001019387A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968470T3 (en) * 2013-03-12 2021-02-01 Massachusetts Gen Hospital MODIFIED MULER INHIBITANT SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES
AU2014321760A1 (en) 2013-09-20 2016-05-05 Massachusetts Eye And Ear Infirmary Uses of modified mullerian inhibiting substance (MIS) proteins for the treatment of neurodegenerative diseases
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US11518793B2 (en) 2016-12-14 2022-12-06 The General Hospital Corporation Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5427780A (en) * 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5484768A (en) * 1990-05-16 1996-01-16 The University Of Melbourne Treatment of male infertility by administration of a muellerian inhibiting substance and surgery and/or hormonal treatment
AU3920693A (en) * 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
JP2947938B2 (en) * 1994-11-28 1999-09-13 旭化成工業株式会社 Optical recording medium

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO0119387A1 *

Also Published As

Publication number Publication date
AU7483000A (en) 2001-04-17
CA2384991A1 (en) 2001-03-22
WO2001019387A1 (en) 2001-03-22
EP1218025A1 (en) 2002-07-03
JP2003509377A (en) 2003-03-11

Similar Documents

Publication Publication Date Title
HUP0202853A3 (en) Use of retigabin for treating neuropathic pain
HUP0201393A3 (en) Use of xenon for treating neurointoxications
GB2364725B (en) Method for treatment of underground reservoirs
HUP0103621A3 (en) Fentanyl composition for the treatment of acute pain
HU0001471D0 (en) New method of treatment
EP1215963A4 (en) Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
IL147541A0 (en) Oligonucleotides for inhibiting the expression of human eg5
PL352931A1 (en) Compositions and uses of et743 for treating cancer
EP1225971A4 (en) Controlled release of substances
IL132173A0 (en) System for treatment of waste
EP1067214A4 (en) Chemical for water treatment and method of water treatment
EP1218025A4 (en) Use of mullerian inhibiting substance for treating excess androgen states
IL149281A0 (en) Treatment of cancer
GB9906808D0 (en) Formulation for treatment of pain
AU1036801A (en) Agent for treating cephalic pain
IL150208A0 (en) Compound and method for the treatment of pain
EP1135141A4 (en) Phospholipase inhibitors for the treatment of cancer
TW465673U (en) Improvement for treating device of liquid
GB9926359D0 (en) Treatment of alopecia
SI1133290T1 (en) Use of inhibitors of acetylcholinesterase for the treatment of deliriums
GB9909906D0 (en) Compositions and methods for treating effluent
TJ99000556A (en) Method of treatment of nevrodermite
GB9915597D0 (en) Method of treatment
GB9903950D0 (en) Method of treatment
GB9917181D0 (en) Methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020415

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050418

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110401